Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Immunology  |  Neurology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Clinical Trials

A listing of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (5) clinical trials

IVIg Treatment-Related Fluctuations in CIDP Patients Using Daily Grip Strength Measurements

Subjects will be recruited by individual site investigators. Prior to enrollment each potential subject will have their screening data reviewed by a panel of medical experts for confirmation of inclusion criteria. Each reviewer will be an independent, board-certified, practicing and experienced neurologist with a special interest in CIDP. Enrolled subjects ...

Phase N/A

Subcutaneous Immunoglobulin for CIDP

Chronic inflammatory demyelinating polyneuropathy (CIDP) is an autoimmune neurological disorder that causes limb weakness and numbness. Many patients require immunosuppressants and plasma exchange (PLEX) to control their symptoms. Intravenous immunoglobulin (IVIG)is also an effective treatment (Hughes et al, 2006 & 2008; Hughes, 2009; Cocito et al, 2010), and the American ...

Phase N/A

Biomark Study: Predict Intravenous Immunoglobulin Responders in Chronic Inflammatory Demyelinating Polyradiculoneuropathy

This study aims analyze the transcriptome to identify predictive biomarkers of IVIG in CIDP patients. 25 patients with a diagnosis of CIDP according to European criteria, nave of treatment, will be included and followed for 1 year. Clinical assessment (RT-MRC ; Martin vigorimeter, RT-mISS,R-ODS,TW25, 9hole-peg test) will be performed at ...

Phase N/A

Transcriptome Analysis of the Peripheral Blood in CIDP

We study the change of the: gene profile on transcriptome analysis of peripheral blood T cell repertory igG dosage immunological profile Before IVIG (T1 time) and and 3 weeks after IVIg treatment (T2 time). On a population of patients having: CIDP, autoimmune muscular disease, Clarkson syndrome, or autoimmune diseases. We ...

Phase N/A